



02-22-07

IAP15 Rec'd PCT/PTO 20 FEB 2007  
PCT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**Applicant:** Merck & Co., Inc.

**Intl. Appln. No.:** PCT/US2004/023780 **US Application:** 10/560,665

**Agents File No.:** 21376YP

**Intl. Filing Date:** July 20, 2004 **US Filing Date:** December 13, 2005

**For:** Antibiotic Compound

**Authorized Officer:**  
TBD

Commissioner of Patents  
Alexandria, VA 22313-1450

Notice of Missing Parts

Sir:

In response to the Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures In compliance with 37 C.F.R. 1.821(f) of the Rules of Practice in Patent Cases: Application Disclosures Containing Nucleotide and/or Amino Acid Sequences, the following statement is being submitted with the computer readable form of Sequence Listing.

I hereby state that the content of the paper and computer readable forms of the Sequence Listing, submitted in accordance 37 C.F.R. 1.821 (c) and (e), respectively, are the same.

In regard to the examination fee. We are with the understanding that all claims satisfy PCT article 33(1)-(4) and therefore no examination fee is due. However, the \$130.00 surcharge fee and any other fees associated with this case maybe charged to Merck Deposit Account No. 13-2755.

EXPRESS MAIL CERTIFICATE  
DATE OF DEPOSIT 2/20/07  
EXPRESS MAIL NO. ED061267869US  
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS  
BEING DEPOSITED WITH THE UNITED STATES POSTAL  
SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE"  
ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO  
COMMISSIONER FOR PATENTS, P.O. BOX 1450,  
ALEXANDRIA, VIRGINIA 22313-1450  
MAILED BY Kathy Kluhoush  
DATE 2-20-07

Respectfully submitted,

By [Signature] 02/23/2007 GFREY 00000111 132755 10560665  
Sylvia A. Ayler  
Reg. No. 36,436  
Attorney for Applicants

Merck & Co., Inc.  
P.O. Box 2000  
Rahway, NJ 07065-0907  
(732) 594-4909

Date: February 20, 2007

# MISC. FEE TRANSMITTAL

Complete if Known

Application Number	10/560,665
Filing Date	December 13, 2005
First Named Inventor	Singh et al.
Examiner Name	TBD
Group Art Unit	TBD
Attorney Docket Number	21376Y

FEB 20 2007

TOTAL AMOUNT OF PAYMENT

\$130

## METHOD OF PAYMENT

☒ Deposit Account

Deposit Account Number 13-2755

Deposit Account Name Merck & Co., Inc.

The Director is authorized to:

☒ Charge fee(s) indicated below

☐ Credit any overpayments

☒ Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17

## FEE CALCULATION

### FEES

Large Entity

Fee Code	Fee (\$)	Fee Description	Fee Paid
1051	130	Surcharge - late filing fee or oath	
1051	130	Non-English Specification	
1812	2,520	For filing a request for <i>ex parte</i> reexamination	
1402	500	Filing a brief in support of an appeal	
1452	500	Petition to revive - unavoidable	
1453	1,500	Petition to revive - unintentional	
1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	Submission of Information Disclosure Statement	
1809	790	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	790	For each additional invention to be examined (37 CFR 1.129(b))	
1840	130	Statutory Terminal Disclaimer under 37 CFR 1.321	
Other fee (specify)		Surcharge to submit a Computer Readable Form of Sequence Listing	130
Other fee (specify)			

TOTAL \$130

## SUBMITTED BY

## Complete (if applicable)

Typed or Printed Name

Sylvia A. Ayler

Reg. Number 36,436

Signature

Date

02/20/2007

Deposit Account User ID

13-2755